http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Lim, J.H.,Shim, J.H.,Choi, J.H.,Park, J.H.,Kim, W.,Joo, J.,Kim, C.J. North-Holland 2009 Physica. C, Superconductivity Vol.469 No.15
We fabricated nano-carbon (NC) doped MgB<SUB>2</SUB> bulks using an in situ process in order to improve the critical current density (J<SUB>c</SUB>) under a high magnetic field and evaluated the correlated effects of the doped carbon content and sintering temperature on the phase formation, microstructure and critical properties. MgB<SUB>2-x</SUB>C<SUB>x</SUB> bulks with x=0 and 0.05 were fabricated by pressing the powder into pellets and sintering at 800<SUP>o</SUP>C, 900<SUP>o</SUP>C, or 1000<SUP>o</SUP>C for 30min. We observed that NC was an effective dopant for MgB<SUB>2</SUB> and that part of it was incorporated into the MgB<SUB>2</SUB> while the other part remained (undoped), which reduced the grain size. The actual C content was estimated to be 68-90% of the nominal content. The NC doped samples exhibited lower T<SUB>c</SUB> values and better J<SUB>c</SUB>(B) behavior than the undoped samples. The doped sample sintered at 900<SUP>o</SUP>C showed the highest J<SUB>c</SUB> value due to its high doping level, small amount of second phase, and fine grains. On the other hand, the J<SUB>c</SUB> was decreased at a sintering temperature of 1000<SUP>o</SUP>C as a result of the formation of MgB<SUB>4</SUB> phase.
Cho, I.,Shim, J.,Chang, H.J.,Sung, J.M.,Hong, Y.,Shim, H.,Kim, Y.J.,Choi, B.W.,Min, J.K.,Kim, J.Y.,Shim, C.Y.,Hong, G.R.,Chung, N. Elsevier Biomedical 2012 JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY - Vol.60 No.21
Objectives: This study was designed to determine the prognostic value of multidetector coronary computed tomography angiography (CTA) in relation to exercise electrocardiography (XECG) findings. Background: The prognostic usefulness of coronary CTA findings of coronary artery disease in relation to XECG findings has not been explored systematically. Methods: Patients with suspected coronary artery disease who had undergone both coronary CTA and XECG (<90 days between tests) from 2003 through 2009 were enrolled retrospectively. Coronary CTA results were classified according to the severity of maximal stenosis (normal, mild: <40% of luminal stenosis, moderate: 40% to 69%, severe: ≥70%), XECG results were categorized as positive and negative, and Duke XECG score was calculated. Clinical follow-up data were collected for major adverse cardiac events (MACE): cardiac death, nonfatal myocardial infarction, unstable angina requiring hospitalization, and revascularization after 90 days from index coronary CTA. C-statistics were calculated to compare discriminatory values of each test. Results: Among the 2,977 (58 +/- 10 years) study patients, 12% demonstrated positive XECG results. By coronary CTA, patients were categorized as normal (56%) or having mild (26%), moderate (13%), or severe (5%) disease. During a median follow-up of 3.3 years (interquartile range: 2.3 to 4.6), 97 MACE were observed and the 5-year cumulative event rate was 3.6% (95% confidence interval: 3.0 to 4.3). Although both XECG (C-statistic: 0.790) and coronary CTA (C-statistic: 0.908) improved risk stratification beyond clinical risk factors (C-statistic: 0.746, p < 0.05 for all), XECG in addition to coronary CTA (C-statistic: 0.907) did not provide better discrimination than coronary CTA alone (p = 0.389). In subgroup analyses, coronary CTA stratified risk of MACE in groups with both positive and negative XECG results (all p < 0.001 for trend). However, positive XECG results predicted risk of MACE on coronary CTA only in the moderate stenosis group (hazard ratio: 2.58, 95% confidence interval: 1.29 to 5.19, p = 0.008) and severe stenosis group (hazard ratio: 2.28, 95% confidence interval: 1.19 to 4.38, p = 0.013). Conclusions: In patients with suspected coronary artery disease, coronary CTA discriminates future risk of MACE in patients independent of XECG results. Compared with coronary CTA, XECG has an additive prognostic value only in patients with moderate to severe stenosis on coronary CTA.
Pharmacokinetics and Mammary Residual Depletion of Erythromycin in Healthy Lactating Ewes
Goudah, A.,Sher Shah, S.,Shin, H.C.,Shim, J.H.,Abd El-Aty, A. M. Blackwell Publishing Ltd 2007 Journal of veterinary medicine. A, Physiology, pat Vol.54 No.10
<P>Summary</P><P>The aim of this investigation was to examine the pharmacokinetics and mammary excretion of erythromycin administered to lactating ewes (<I>n</I> = 6) by the intravenous (i.v.), intramuscular (i.m.) and subcutaneous (s.c.) routes at a dosage of 10 mg/kg. Blood and milk samples were collected at pre-determined times, and a microbiological assay method was used to measure erythromycin concentrations in serum and milk. The concentration–time data were analysed by compartmental and non-compartmental kinetic methods. The serum concentration–time data of erythromycin were fit to a two-compartment model after i.v. administration and a one-compartment model with first-order absorption after i.m. and s.c. administration. The elimination half-life (<I>t</I><SUB>1/2&bgr;</SUB>) was 4.502 ± 1.487 h after i.v. administration, 4.874 ± 0.296 h after i.m. administration and 6.536 ± 0.151 h after s.c. administration. The clearance value (Cl<SUB>tot</SUB>) after i.v. dosing was 1.292 ± 0.121 l/h/kg. After i.m. and s.c. administration, observed peak erthyromycin concentrations (<I>C</I><SUB>max</SUB>) of 0.918 ± 0.092 <I>&mgr;</I>g/ml and 0.787 ± 0.010 <I>&mgr;</I>g/ml were achieved at 0.75 and 1.0 h (<I>T</I><SUB>max</SUB>) respectively. The bioavailability obtained after i.m. and s.c. administration was 91.178 ± 10.232% and 104.573 ± 9.028% respectively. Erythromycin penetration from blood to milk was quick for all the routes of administration, and the high AUC<SUB>milk</SUB>/AUC<SUB>serum</SUB> (1.186, 1.057 and 1.108) and C<SUB>max‐milk</SUB>/C<SUB>max‐serum</SUB> ratios reached following i.v., i.m. and s.c. administration, respectively, indicated an extensive penetration of erythromycin into the milk.</P>
Surface characteristics of titanium–silver alloys in artificial saliva
Shim, H. M.,Oh, K. T.,Woo, J. Y.,Hwang, C. J.,Kim, K. N. Heyden & Son 2006 Surface and interface analysis Vol.38 No.1
<P>Titanium and its alloys are widely used in biomedical and dental fields because of their excellent corrosion resistance and biocompatibility. It is well known that titanium is protected from corrosion because of the stability of the passive film that controls and determines the corrosion resistance and biocompatibility of titanium and its alloys. The purpose of this study was to evaluate the electrochemical properties of titanium–silver alloys and the surface characteristics of passive film in artificial saliva.</P><P>We designed titanium–silver alloys with silver contents ranging from 0 to 5 at.%, in 1% increments. These alloys were arc-melted, homogenized, hot-rolled to 2 mm thickness, and finally solution heat-treated for 1 h and quenched. Potentiostatic testing was performed, and the open circuit potentials of the alloys were measured in artificial saliva, at 37 °C. The passive films of the titanium–silver alloys were analyzed via XPS.</P><P>Titanium–silver alloys maintained low current density and showed stable passive region and also had high open circuit potential as compared with pure titanium. The open circuit potential of titanium–silver alloys increased as silver addition increased. With regard to the fraction of oxygen species, a component of over 80% was found to be comprised of oxide. Therefore, the titanium surface mainly consisted of titanium oxide and, on the titanium–silver alloys, this film was composed of TiO<SUB>2</SUB>, Ti<SUB>2</SUB>O<SUB>3</SUB>, and TiO. As silver content increased, the TiO<SUB>2</SUB> fraction also increased, as did the thickness of the titanium oxide layer formed. Copyright © 2005 John Wiley & Sons, Ltd.</P>